-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read and refer to it as soon as possible~ On April 9, the 2021 National Breast Cancer Conference and the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Annual Conference will be held in Beijing as scheduled.
The CSCO BC Annual Conference is one of the most influential academic events in the field of breast cancer in China.
The conference was conducted in the form of "online + offline", and special academic exchange sessions were set up for scientific frontiers, new drug development, perspectives of famous experts, and diagnosis and treatment guidelines.
Highlights are frequent and brilliant.
At the press conference of the 2021 National Breast Cancer Conference held in the evening, the high-profile "2021 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines" and "Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Clinical Diagnosis and Treatment Expert Consensus 2021" Edition", "Consensus of Chinese Experts on Breast Cancer Bone Metastasis" and "CSCO AI for BC 2021" artificial intelligence-assisted decision-making system updates have been released one after another.
The chairman of the conference, the vice chairman of CSCO, the chairman of the CSCO breast cancer expert committee, and Professor Jiang Zefei from the Department of Oncology of the PLA General Hospital on the "2021 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines", "Breast Cancer Bone Metastasis Chinese Expert Consensus", etc.
The main points of the content were shared, and a number of CSCO BC committee leaders attended the press conference of the conference.
"2021 CSCO BC Diagnosis and Treatment Guidelines" Update Points The 2021 version of the guidelines continues to be updated on the basis of the past, based on the principles of evidence-based, balanced access, and expert opinions, ensuring the scientificity and timeliness of the guidelines.
This guide has updated many contents in pathological diagnosis to provide more basis for clinical diagnosis and treatment.
In molecular typing, the definition of HER-2 low expression was added, the ER weakly positive interpretation was added, and the Ki-67 evaluation criteria were updated.
Patients with low expression of HER-2 may benefit from new antibody-conjugated drug treatments, and clinical studies have been ongoing.
Therefore, on the basis of the original definition of HER-2 negative in the clinic, patients with HER-2 IHC 1+ or IHC 2+ and ISH negative are defined as HER-2 low expression, and an IHC result of 0 is defined as HER-2 negative .
Added the evaluation of PD-L1 in breast cancer.
Clinical studies have shown that PD-L1 expression level may be related to the efficacy of PD-1/PD-L1 inhibitors, and the accuracy of PD-L1 expression level will affect the subsequent treatment of patients.
Pathological evaluation after neoadjuvant treatment of breast cancer was newly added.
The commonly used evaluation system in China is the Miller & Payne evaluation system, and the evaluation method recommended by the International Breast Collaboration Group is the RCB (Residual Cancer Burden) evaluation system.
In the treatment and management of breast cancer, new tyrosine kinase inhibitor (TKI) adverse reaction management, CDK4/6 inhibitor adverse reaction management, and chidamide adverse reaction management have been added.
A new real-world study (RWS) has been added.
RWS and randomized controlled studies can complement each other and provide more comprehensive evidence for clinical diagnosis and treatment.
Newly added biosimilar drugs, the indication extrapolation of biosimilar drugs should select sensitive indication populations for clinical trials, and the mechanism and targets of different indications are the same.
At the same time, the safety and immunogenicity of biosimilar drugs should be carried out.
Fully evaluate.
In addition, the management of breast cancer patients under normalized epidemic prevention and control and artificial intelligence-assisted diagnosis and treatment decision-making have been added.
The expert consensus on clinical diagnosis and treatment of HER-2 positive breast cancer (2021) has updated the clinical proportion of HER-2 positive breast cancer to about 20%.
In recent years, new anti-HER-2 therapies such as Pertuzumab, Lapatinib, Pirotinib and Enmetrastuzumab (TDM-1) have been continuously developed and approved for marketing.
Good treatment results have been achieved in the treatment. However, standard treatment is the prerequisite for ensuring the efficacy.
In order to better standardize the clinical and reasonable diagnosis and treatment of HER-2 positive breast cancer, to achieve "appropriate population, appropriate time, and appropriate plan", the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology and the Chinese Anti-Cancer Association The Breast Cancer Professional Committee updated this consensus for reference by colleagues at home and abroad.
The "Consensus of Chinese Experts on Bone Metastasis of Breast Cancer" was released.
The "Consensus of Chinese Experts on Bone Metastasis of Breast Cancer" was released, which firstly updated the bone-related events (SREs).
In the 2014 Chinese Consensus, bone pain and hypercalcemia were often considered SRE in early clinical studies of bone modification drugs.
In the 2020 version of the China Consensus, the SRE clearly stipulated in the U.
S.
Food and Drug Administration (FDA) "Research Endpoint Guidelines for Clinical Trials of Cancer Drugs" includes pathological fractures, bone surgery, bone radiotherapy, and spinal cord compression.
In addition, in the application of bone-modifying drugs, the 2020 Chinese consensus recommends the use of disulumab.
In November 2020, NMPA approved disulumab (120mg) for the prevention of bone metastasis of solid tumors and SRE caused by multiple myeloma.
Therefore, the 2020 version of the Chinese consensus recommends the use of disulumab.
Before applying bone-modifying drugs, attention should be paid to correct existing hypocalcemia, and patients should be advised to supplement calcium and vitamin D.
"CSCO AI for BC 2021" artificial intelligence assistant decision-making system is updated and released.
The CSCO Breast Cancer Special Committee successfully developed the CSCO AI intelligent decision-making system using the CSCO BC guidelines and database, and completed the preliminary verification of the system.
At present, the system has formed the important functions of intelligent decision-making, evidence support, adverse reactions, cost reference, and patient follow-up.
Effectively help cancer patients everywhere to obtain better diagnosis and treatment services, and help my country's cancer diagnosis and treatment norms to be wider, deeper and easier to operate.
And to carry out the training of smart doctors in many places across the country.
The advantage of this system lies in the "norm", which makes decisions for individuals based on guidelines.
At present, CSCO AI has carried out nearly 10,000 applications to help reduce the direct diagnosis and treatment costs of patients and improve the survival prognosis.
It can be seen that the new version of the guidelines combines the latest international and domestic research and is more in line with the needs of clinical practice, laying the foundation for the standardization of breast cancer diagnosis and treatment.
With the update of the CSCO BC guidelines and the promulgation of the CSCO AI artificial intelligence system, with the help of the CSCO BC guidelines and the artificial intelligence system, the standardized diagnosis and treatment of breast cancer in China will be further enhanced and popularized, enabling more doctors and patients across the country Benefit.
The CSCO BC Annual Conference is one of the most influential academic events in the field of breast cancer in China.
The conference was conducted in the form of "online + offline", and special academic exchange sessions were set up for scientific frontiers, new drug development, perspectives of famous experts, and diagnosis and treatment guidelines.
Highlights are frequent and brilliant.
At the press conference of the 2021 National Breast Cancer Conference held in the evening, the high-profile "2021 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines" and "Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Clinical Diagnosis and Treatment Expert Consensus 2021" Edition", "Consensus of Chinese Experts on Breast Cancer Bone Metastasis" and "CSCO AI for BC 2021" artificial intelligence-assisted decision-making system updates have been released one after another.
The chairman of the conference, the vice chairman of CSCO, the chairman of the CSCO breast cancer expert committee, and Professor Jiang Zefei from the Department of Oncology of the PLA General Hospital on the "2021 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines", "Breast Cancer Bone Metastasis Chinese Expert Consensus", etc.
The main points of the content were shared, and a number of CSCO BC committee leaders attended the press conference of the conference.
"2021 CSCO BC Diagnosis and Treatment Guidelines" Update Points The 2021 version of the guidelines continues to be updated on the basis of the past, based on the principles of evidence-based, balanced access, and expert opinions, ensuring the scientificity and timeliness of the guidelines.
This guide has updated many contents in pathological diagnosis to provide more basis for clinical diagnosis and treatment.
In molecular typing, the definition of HER-2 low expression was added, the ER weakly positive interpretation was added, and the Ki-67 evaluation criteria were updated.
Patients with low expression of HER-2 may benefit from new antibody-conjugated drug treatments, and clinical studies have been ongoing.
Therefore, on the basis of the original definition of HER-2 negative in the clinic, patients with HER-2 IHC 1+ or IHC 2+ and ISH negative are defined as HER-2 low expression, and an IHC result of 0 is defined as HER-2 negative .
Added the evaluation of PD-L1 in breast cancer.
Clinical studies have shown that PD-L1 expression level may be related to the efficacy of PD-1/PD-L1 inhibitors, and the accuracy of PD-L1 expression level will affect the subsequent treatment of patients.
Pathological evaluation after neoadjuvant treatment of breast cancer was newly added.
The commonly used evaluation system in China is the Miller & Payne evaluation system, and the evaluation method recommended by the International Breast Collaboration Group is the RCB (Residual Cancer Burden) evaluation system.
In the treatment and management of breast cancer, new tyrosine kinase inhibitor (TKI) adverse reaction management, CDK4/6 inhibitor adverse reaction management, and chidamide adverse reaction management have been added.
A new real-world study (RWS) has been added.
RWS and randomized controlled studies can complement each other and provide more comprehensive evidence for clinical diagnosis and treatment.
Newly added biosimilar drugs, the indication extrapolation of biosimilar drugs should select sensitive indication populations for clinical trials, and the mechanism and targets of different indications are the same.
At the same time, the safety and immunogenicity of biosimilar drugs should be carried out.
Fully evaluate.
In addition, the management of breast cancer patients under normalized epidemic prevention and control and artificial intelligence-assisted diagnosis and treatment decision-making have been added.
The expert consensus on clinical diagnosis and treatment of HER-2 positive breast cancer (2021) has updated the clinical proportion of HER-2 positive breast cancer to about 20%.
In recent years, new anti-HER-2 therapies such as Pertuzumab, Lapatinib, Pirotinib and Enmetrastuzumab (TDM-1) have been continuously developed and approved for marketing.
Good treatment results have been achieved in the treatment. However, standard treatment is the prerequisite for ensuring the efficacy.
In order to better standardize the clinical and reasonable diagnosis and treatment of HER-2 positive breast cancer, to achieve "appropriate population, appropriate time, and appropriate plan", the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology and the Chinese Anti-Cancer Association The Breast Cancer Professional Committee updated this consensus for reference by colleagues at home and abroad.
The "Consensus of Chinese Experts on Bone Metastasis of Breast Cancer" was released.
The "Consensus of Chinese Experts on Bone Metastasis of Breast Cancer" was released, which firstly updated the bone-related events (SREs).
In the 2014 Chinese Consensus, bone pain and hypercalcemia were often considered SRE in early clinical studies of bone modification drugs.
In the 2020 version of the China Consensus, the SRE clearly stipulated in the U.
S.
Food and Drug Administration (FDA) "Research Endpoint Guidelines for Clinical Trials of Cancer Drugs" includes pathological fractures, bone surgery, bone radiotherapy, and spinal cord compression.
In addition, in the application of bone-modifying drugs, the 2020 Chinese consensus recommends the use of disulumab.
In November 2020, NMPA approved disulumab (120mg) for the prevention of bone metastasis of solid tumors and SRE caused by multiple myeloma.
Therefore, the 2020 version of the Chinese consensus recommends the use of disulumab.
Before applying bone-modifying drugs, attention should be paid to correct existing hypocalcemia, and patients should be advised to supplement calcium and vitamin D.
"CSCO AI for BC 2021" artificial intelligence assistant decision-making system is updated and released.
The CSCO Breast Cancer Special Committee successfully developed the CSCO AI intelligent decision-making system using the CSCO BC guidelines and database, and completed the preliminary verification of the system.
At present, the system has formed the important functions of intelligent decision-making, evidence support, adverse reactions, cost reference, and patient follow-up.
Effectively help cancer patients everywhere to obtain better diagnosis and treatment services, and help my country's cancer diagnosis and treatment norms to be wider, deeper and easier to operate.
And to carry out the training of smart doctors in many places across the country.
The advantage of this system lies in the "norm", which makes decisions for individuals based on guidelines.
At present, CSCO AI has carried out nearly 10,000 applications to help reduce the direct diagnosis and treatment costs of patients and improve the survival prognosis.
It can be seen that the new version of the guidelines combines the latest international and domestic research and is more in line with the needs of clinical practice, laying the foundation for the standardization of breast cancer diagnosis and treatment.
With the update of the CSCO BC guidelines and the promulgation of the CSCO AI artificial intelligence system, with the help of the CSCO BC guidelines and the artificial intelligence system, the standardized diagnosis and treatment of breast cancer in China will be further enhanced and popularized, enabling more doctors and patients across the country Benefit.
